✦ LIBER ✦

Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients

✍ Scribed by Vincent F. Guinee; Kenneth R. Hess; Richard M. Elledge; Gregory Langone; Daniel R. Ciocca

Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 235 KB
Volume: 72
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19931001)72:7<2291::aid-cncr2820720742>3.0.co;2-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

c-erbB-2 (HER-2/neu) protein and drug re

c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy

✍ Laura M. Vargas-Roig; Francisco E. Gago; Olga Tello; María T. Martin de Civetta; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 71 KB 👁 1 views

Expression of c-erbB-2 protein has been associated with poor prognosis and poor response to chemotherapy in breast cancer patients. In the present prospective study, we have analyzed whether c-erbB-2, p53 and P170 proteins may be determinants of tumor resistance in locally advanced breast cancer pat

Estrogen receptor (ER) and progesterone

Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study

✍ Richard M. Elledge; Stephanie Green; Reginald Pugh; D. Craig Allred; Gary M. Cla 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 133 KB 👁 2 views

Results of estrogen receptor (ER) and progesterone receptor (PgR) ligand-binding assays (LBAs) are strongly correlated with ER and PgR by immuno-histochemistry (IHC). To investigate whether ER and PgR by IHC are also strongly correlated with tamoxifen response, time to treatment failure (TTF) and ov